Physician profile
Pete Banchuin
NPI 1568811024
$828.07
in general payments reported to CMS, 2019-2025
13 companies · $41.92 in 2025
The $41.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.24 · 2020: $394 · 2021: $143 · 2022: $91.83 · 2023: $88.98 · 2025: $41.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218.03 | 2019-2022 | |
| Amgen INC. | $149.87 | 2019-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $142.89 | 2020-2021 | |
| Pfizer INC. | $67.73 | 2020-2023 | |
| Lilly USA, LLC | $65.93 | 2020-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $43.75 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.92 | 2025 | Capvaxive, Gardasil 9, M-M-R II |
| Esperion Therapeutics, INC. | $32.46 | 2020-2022 | |
| Eisai INC. | $13.94 | 2020 | |
| Abbott Laboratories | $13.76 | 2021 | |
| Daiichi Sankyo INC. | $12.99 | 2020 | |
| Phadia US INC. | $12.99 | 2020 | |
| Amarin Pharma, INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pete Banchuin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.